Outlook Therapeutics, FDA Reddinden Sonra Yeni İlaçla Milyar Dolarlık Oftalmoloji Pazarını Hedefliyor

Outlook Therapeutics Targets Multibillion Dollar Ophthalmology Market With New Drug After FDA Rejection

Vandana Singh

Wed, July 29, 2026 at 12:31 AM GMT+3 5 min read

OTLK +10.62%

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.

On Friday, the U.S. Food and Drug Administration (FDA) approved Outlook Therapeutics Inc.'s ONS-5010/LYTENAVA (bevacizumab-vikg, bevacizumab gamma) for neovascular age-related macular degeneration (nAMD), commonly known as wet AMD.

The regulatory milestone distinguishes LYTENAVA as the inaugural and sole FDA-approved ophthalmic formulation of bevacizumab designed specifically for wet AMD treatment within the United States.

The approval comes after the drug has received three FDA rejections.

Don't Miss:

A single bad hire can set a startup back years. Here are the 5 hires founders most often misjudge — and why
Still Learning the Market? These 50 Must-Know Terms Can Help You Catch Up Fast

Setting New Standard in Retina Care

For the first time, retina specialists and patients have an FDA-backed bevacizumab option tailored exclusively for ocular use.

Consequently, the biopharmaceutical firm anticipates securing 12 years of Reference Product Exclusivity under the Biologics Price Competition and Innovation Act.

LYTENAVA is strategically positioned to become the premier FDA-approved bevacizumab therapy for wet AMD. Presently, bevacizumab constitutes the bulk of initial anti-VEGF treatments for the disease, highlighting its critical function in retinal health.

"For more than two decades, bevacizumab has served as one of the most widely utilized anti-VEGF therapies in retina care despite the absence of an FDA-approved ophthalmic formulation. LYTENAVA fundamentally changes that landscape," said Bob Jahr, CEO of Outlook Therapeutics.

"Rather than relying on repackaged formulations originally intended for intravenous use, physicians now have access to a purpose-built ophthalmic formulation of bevacizumab designed specifically for intravitreal administration that delivers the manufacturing consistency, product quality, and regulatory oversight patients deserve," Jahr further commented.

Entering Multibillion-Dollar Market

Wet AMD remains a persistent, advancing disease and a primary driver of severe vision impairment among older demographics globally. Because patients frequently require sustained therapies over many years, consistent manufacturing and product reliability are vital.

LYTENAVA is stepping into a highly lucrative ophthalmology sector. The domestic anti-VEGF retina market generates roughly $8.5 billion annually, involving millions of intravitreal injections every year.

Following the approval, the enterprise is initiating its commercial rollout. Operations will focus on broadening patient access, enhancing reimbursement strategies, and building a specialized commercial retina team.

Eligible patients nationwide are expected to have access to LYTENAVA before the close of the year.

Photo by Panchenko Vladimir via Shutterstock

Read Next:

Skip the Regrets: The Essential Retirement Tips Experts Wish Everyone Knew Earlier.
Think you're saving enough for your kids? You might be dangerously off — see why

Building Wealth Across More Than Just the Market

Building a resilient portfolio means thinking beyond a single asset or market trend. Economic cycles shift, sectors rise and fall, and no one investment performs well in every environment. That's why many investors look to diversify with platforms that provide access to real estate, fixed-income opportunities, precious metals, and even self-directed retirement accounts. By spreading exposure across multiple asset classes, it becomes easier to manage risk, capture steady returns, and create long-term wealth that isn't tied to the fortunes of just one company or industry.

Arrived

Backed by Jeff Bezos, Arrived Homes makes real estate investing accessible with a low barrier to entry. Investors can buy fractional shares of single-family rentals and vacation homes starting with as little as $100. This allows everyday investors to diversify into real estate, collect rental income, and build long-term wealth without needing to manage properties directly.

Realberry

Institutional-quality real estate has traditionally been difficult for individual investors to access. Realberry gives accredited investors direct access to private real estate opportunities backed by a team with 35 years of experience, $3.4 billion in assets under management, and $481 million in cumulative distributions paid to investors as of Q4 2025, according to the company. With a portfolio spanning 13 million square feet across seven U.S. states, Realberry focuses on acquiring, developing, and managing real estate with an emphasis on long-term value creation while its principals often invest alongside clients to help align interests.

FarmTogether

Farmland has historically held its value through market volatility and delivered returns uncorrelated to stocks and bonds. For accredited investors, FarmTogether offers direct access to high-quality U.S. farmland starting at $15,000 — fully managed, with no landlord headaches.

Immersed

Immersed is building technology for the future of work through spatial computing. Known for its AR/VR productivity platform that enables users to work across multiple virtual screens, the company has grown to more than 1.5 million users worldwide. Immersed is also developing Visor, a lightweight headset designed specifically for professional productivity, positioning the company at the intersection of remote work, extended reality (XR), and next-generation computing.

Fundrise

Private real estate and private credit can add income and stability to a stock-heavy portfolio. Fundrise offers access to diversified private real estate and credit strategies through an easy-to-use platform, with professionally managed portfolios designed to generate passive income and long-term growth.

Mode Mobile

Mode Mobile is changing the way people interact with their phones by letting users earn money from the same apps and activities they already use every day. Instead of platforms keeping all the advertising revenue, Mode Mobile shares a portion back with users who engage with content, play games, and scroll on their devices. Named one of Deloitte's fastest-growing software companies in North America, the company has built a large beta user base and is scaling a model that turns everyday smartphone usage into a potential income stream.

EquityMultiple

For accredited investors looking beyond stocks and bonds, EquityMultiple provides access to vetted commercial real estate deals starting at $5,000, with only ~5% of opportunities passing their due diligence process.